Few notable successes in this field include the identification of trastuzumab-responsive breast cancers by testing for Her2-neu, BCR/ABl translocation in chronic myeloid leukemia, and KIT mutations in imatinib-responsive GIST [31]. This evidence concerns the gene KIT and gastrointestinal stromal tumor.